Dr. Darius Moshfeghi MD

Practice: Byers Eye Institute

Location: Palo Alto, California

Website: https://med.stanford.edu/

Phone: 650-723-6995

Email: dariusm@stanford.edu

"Dr. Darius M. Moshfeghi is Chief of the Retina Division and Professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, at the Stanford University School of Medicine. Dr. Moshfeghi received training in biomedical engineering as an undergraduate at Tulane University in New Orleans, followed by medical school, internship, and ophthalmology residency also at Tulane. Subsequently he performed fellowships in ocular oncology and orbital disease, followed by a 2-year vitreoretinal surgery fellowship at the Cole Eye Institute of the Cleveland Clinic Foundation. He was introduced to the concept of wide-angle imaging and its potential for telemedicine in pediatric retinal disease while treating patients with retinoblastoma at St. Jude Children's Research Hospital in Memphis, Tennessee. He is an internationally-recognized expert in pediatric vitreoretinal disease and pediatric retinal telemedicine. He has dedicated his career to using telemedicine and digital technology to prevent blindness in children.

He founded the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) program in 2005, and today it remains the oldest and largest telemedicine screening program for ROP in the United States. He has developed a national telemedicine screening program for Pediatrix with Stanford University for ROP called TELEROP. He has worked with industry both in a consultative and creative-founder role to develop wide-angle imaging camera technology as well as deep learning classifier platforms for the identification of disease in healthy term newborn infants.

He is actively involved in entrepreneurial activities, serving as a founder and a director of Pr3vent, Placid0, dSentz, and Promisight. He is actively engaged in promoting telemedicine to expand access of eye care and vision for all. He currently serves on the American Academy of Ophthalmology (AAO) Telemedicine Working Group and previously sat on the AAO's ROP Telemedicine Task Force Panel. Additionally he is a founding member of the Collaborative Community on Ophthalmic Imaging a collaboration between stake holders and the FDA which was established by Mark Blumenkranz here at Stanford University.

He has collaborated extensively with the pharmaceutical industry in oversight (Alcon and Novartis Data Safety Monitoring Committees for Brolucizumab, Novartis Safety Review Committee Brolucizumab), steering committees (Regeneron Butterfleye, Bayer Photographic Committee for Firefleye, Iconic Therapeutics, Pykus), and drug development (Alexion).

Finally, Dr. Moshfeghi is interested in medical training and mentoring of individuals pursuing careers in medicine and biomedical spaces. He was the founding director of the Stanford Vitreoretinal Surgery and Medical Disease Fellowship and remains actively engaged in the day-to-day training of the fellows and works extensively with medical students (and has served as a MedScholars mentor for many students) and visiting fellows.

    • Retinopathy of Prematurity

    • Progressive Myopia

    • Familial Exudative Vitreoretinopathies

    • Norrie syndrome

    • Stickler syndrome

    • Age Related Macular Degeneration

    • Retinal Vein Occlusion

    • Diabetic Retinopathy

    • Ophthalmology

    • Academic Appointments

    • Professor - University Medical Line, Ophthalmology

    • Member, Bio-X

    • Administrative Appointments

    • Board Recertification, American Board of Ophthalmology, Ophthalmology (2020)

    • Board Recertification, American Board of Ophthalmology, Ophthalmology (2010)

    • Board Certification: American Board of Ophthalmology, Ophthalmology (2000)

    • Fellowship: Cleveland Clinic Foundation Heart Center (2002) OH

    • Fellowship, Cleveland Clinic, Vitreoretinal Surgery (2002)

    • Fellowship: St Jude Children's Research Hospital (2000) TN

    • Fellowship, Univ. Tenn. Memphis/St. Jude, Oncology & Orbital Disease (2000)

    • Residency: Tulane Medical Center (1999) LA

    • Ophthalmology, Tulane University, Ophthalmology (1999)

    • Internship: Tulane Medical Center (1996) LA

    • Internship, Tulane University, Transitional (Rotating) Internship (1996)

    • Medical Education: Tulane University School of Medicine Registrar (1995) LA

    • MD, Tulane University, Medicine (1995)

    • B.S.Eng., Tulane University, Biomedical Engineering (1991)"

  • Administrative Appointments

    • Chief of Retina Division: Vitreoretinal Surgery & Medical Diseases, Byers Eye Institute, Stanford University School of Medicine (2017 - Present)

    • Chief of Pediatric Vitreoretinal Surgery & Medical Diseases, Byers Eye Institute, Horngren Vitreoretinal Center, Dept. of Ophthalmology, Stanford University (2011 - Present)

    • Director of Ophthalmologic Telemedicine, Byers Eye Institute, Horngren Vitreoretinal Center, Dept. of Ophthalmology, Stanford University (2011 - 2017)

    • Founder, Director of Vitreoretinal Surgical & Medical Diseases Fellowship, Byers Eye Institute, Horngren Vitreoretinal Center, Dept. of Ophthalmology, Stanford University (2009 - 2017)

    • Founder & Director, Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) (2005 - Present)

    Honors & Awards

    • America's Top Doctors, Ophthalmology, Castle Connolly Medical, LTD (2022)

    • Inductee, Retina Hall of Fame (2021)

    • Retina 150 Innovators, Ocular Surgery News (2016)

    • Senior Achievement Award, American Academy of Ophthalmology (2015)

    • Outstanding Tulane Eye Alumnus, Department of Ophthalmology, Tulane University School of Medicine (2014)

    • Senior Honor Award, American Society of Retina Specialists (2013)

    • Best Doctors, Best Doctors, Inc. (2009-2017)

    • Honor Award, American Society of Retina Specialists (2009)

    • Achievement Award, American Academy of Ophthalmology (2008)

    • Best Poster, American Academy of Ophthalmology (2007)

    • America's Top Ophthalmologists, Consumers' Research Council of America (2004-2005, 2007-2008, 2009)

    • Editor's Choice, American Academy of Ophthalmology (2003)

    • ARVO Travel Grant, National Eye Institute (2002)

    • Paul Kayser International Scholar, Pan-American Academy of Ophthalmology (2002)

    • Fellow, Ronald G. Michels Fellowship Foundation (2001-2002)

    • Fellow, Heed Ophthalmic Foundation (2000-2001)

    • Dean's Honor Scholarship, Tulane University (1987-1991)

    • Boards, Advisory Committees, Professional Organizations

    • Member, Collaborative Community on Ophthalmic Imaging-ROP Section (2019 - Present)

    • Member, Telemedicine Working Group, American Academy of Ophthalmology (2014 - Present)

FAQ

At the Jack McGovern Coats’ Disease Foundation, we are often contacted by anxious parents or patients who are seeking information after receiving a diagnosis of Coats’ Disease. The questions below are provided as a resource to assist you as you and your doctor decide the best approach for treatment. These questions do not constitute any form of medical advice or diagnosis. Each patient is unique. An experienced retinal specialist who has examined the patient is the best source of information for diagnosis and treatment. We always recommend getting a second opinion.

Questions to Ask Your Doctor (Download PDF)

  • Ahead of any treatments or procedures, it is important to ask yourself and the doctor the following questions:

    • How do you know that this is Coats’ Disease?

    • Has your doctor treated other patients with Coats’ Disease?

    • Have you sought a second opinion? If not, please consult our Doctor Directory for knowledgeable doctors in your area.

    • What Stage of Coats’ Disease is he/she in?

    • Will his/her vision get worse over time?

    • Will the eye have pain?

    • Will his/her eye start to turn out? Is muscle corrective surgery an option?

    • Are cataracts likely?

    • How likely is glaucoma? (due to retinal detachment)

    • Is there calcification?

    • What is the anticipated disease progression?

    • Is there a thorough vision exam available?

    • Where is the vision affected? (central/peripheral/distance)

    • Does he/she have depth perception? (3D visibility)

    • What about the non-Coats’ eye?

    • To what extent is his/her vision affected?

    • Will we be able to use this as a baseline to measure progress/decline?

Find a Doctor

Are you a Doctor?

Contact us to learn more about taking the White Coats to Cure Coats pledge today.